Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MRG 110

Drug Profile

MRG 110

Alternative Names: Anti Mir92a; MRG-110; S95010

Latest Information Update: 22 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Texas Southwestern Medical Center
  • Developer miRagen Therapeutics; Servier; University of Texas Southwestern Medical Center
  • Class Anti-ischaemics; Cardiovascular therapies; Heart failure therapies; Ischaemic heart disorder therapies; MicroRNAs
  • Mechanism of Action MicroRNA inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Heart failure; Ischaemia; Wounds

Most Recent Events

  • 16 Oct 2019 Efficacy and adverse events data from a phase I trial in Wounds and Ischaemia released by miRagen Therapeutics
  • 13 Mar 2019 miRagen Therapeutics and Servier completes enrolment in its phase I trial for Heart failure in USA
  • 13 Mar 2019 miRagen Therapeutics and Servier completes enrolment in its phase I trial for Wounds in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top